Syngene International Extends Strategic Partnership with Bristol Myers Squibb Until 2035

In a significant development for the biopharmaceutical industry, Syngene International, a leading global contractual research, development, and manufacturing organization (CRDMO), has announced the extension of its long-term strategic partnership with Bristol Myers Squibb (BMS) until 2035. This milestone marks an essential step in fostering further collaboration in the drug development arena, focusing on integrated services that encompass the entire drug lifecycle.

The renewed contract enhances the collaboration by broadening the scope of integrated services that Syngene provides to BMS, which includes drug substance research (spanning chemistry, biology, drug metabolism, and pharmacokinetics), translational sciences, pharmaceutical development, clinical trials, and data and IT services. Such a comprehensive array of services is poised to ensure a seamless transition of research into commercialization, providing both partners with a significant competitive edge in the market.

Peter Bains, CEO of Syngene International Ltd., expressed his enthusiasm for the partnership, stating, "Our collaboration with Bristol Myers Squibb, which has now lasted more than 25 years, is built on scientific excellence, reliable operations, and a shared commitment to advancing innovative therapies. Extending this partnership through 2035 enables us to plan for the future and build new capacities and infrastructure with a ten-year horizon. The long-term vision is a key feature of our partnership that provides strategic value for both companies. We are excited to support BMS in the next wave of drug discovery, development, and manufacturing programs that have the potential to improve patient outcomes globally."

Payal Sheth, Senior Vice President at Bristol Myers Squibb’s Therapeutic Discovery Sciences, reaffirmed the commitment to patient-centered drug development, emphasizing that the collaboration with Syngene has played a crucial role in advancing their scientific ambitions. She remarked, "This extended collaboration underscores our commitment to advancing innovative science by effectively integrating our research, development, and manufacturing capabilities to accelerate transformative drug delivery, thereby offering hope to patients worldwide who are awaiting new treatment options."

The partnership between Syngene and BMS dates back to 1998, leading to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene's first dedicated research and development facility, which began full operations in 2009. Over the years, the BBRC has evolved into a vital strategic R&D site for BMS, showcasing integrated capabilities in target identification, drug discovery, lead optimization, pharmaceutical development, molecular and cellular biology, protein sciences, bioassays, and clinical biomarkers. Today, approximately 700 scientists from Syngene work at the BBRC as an extension of BMS's global research organization, making significant contributions to the discovery, preclinical development, and patent filings in therapeutic areas such as cardiovascular diseases, fibrosis, immunology, and oncology.

Since its inception, the BBRC has played a pivotal role in expediting the development of novel drug candidates from early discovery to first-in-human studies, thereby significantly reducing Bristol Myers Squibb’s development timelines and overall costs.

More About Syngene International

Syngene International Ltd. (BSE 539268, NSE SYNGENE, ISIN INE 398R01022) is a comprehensive research, development, and manufacturing service company operating across pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. With over 8,200 employees—of which 5,600 are scientists—Syngene leverages deep expertise and world-class capabilities to deliver scientific excellence, robust data security, and manufacturing on a global scale, all aimed at reducing time-to-market and innovation costs.

With more than 232,000 square feet of specialized facilities for drug research, development, and manufacturing located in India and the USA, Syngene collaborates with 400 clients across various industrial segments, including biotech firms leading cutting-edge research and multinational corporations like BMS, GSK, Zoetis, and Merck KGaA. Further information about Syngene can be found at www.syngeneintl.com. For the latest ESG report by Syngene, you can view it at the Syngene ESG Report.